Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Dec;23(12):e164-e165.
doi: 10.1634/theoncologist.2017-0316. Epub 2018 Jun 12.

Pertuzumab: Getting the Balance Right

Jamal Zekri  1 , Ehab M Abdelghany  2 , Farah Abed-Alsater  3
Affiliations
Comment

Pertuzumab: Getting the Balance Right

Jamal Zekri et al. Oncologist. 2018 Dec.
No abstract available

PubMed Disclaimer

Comment in

  • In Reply.
    Dang CT, Singh JC, Steingart RM, Yu AF. Dang CT, et al. Oncologist. 2018 Dec;23(12):e165-e166. doi: 10.1634/theoncologist.2018-0101. Epub 2018 Aug 17. Oncologist. 2018. PMID: 30120162 Free PMC article. No abstract available.

Comment on

References

    1. Yu AF, Singh JC, Wang R et al. Cardiac safety of dual anti‐HER2 therapy in the neoadjuvant setting for treatment of HER2‐positive breast cancer. The Oncologist 2017;22:642–647. - PMC - PubMed
    1. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2‐positive breast cancer (NeoSphere): A randomised multicentre, open‐label, phase 2 trial. Lancet Oncol 2012;13:25–32. - PubMed
    1. Swain SM, Ewer MS, Cortés J et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2‐positive metastatic breast cancer in CLEOPATRA: A randomized, double‐blind, placebo‐controlled phase III study. The Oncologist 2013;18:257–264. - PMC - PubMed
    1. Swain SM, Baselga J, Kim SB et al.; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2‐positive metastatic breast cancer. N Engl J Med 2015;372:724–734. - PMC - PubMed
    1. Gianni L, Pienkowski T, Im YH et al. 5‐year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early‐stage HER2‐positive breast cancer (NeoSphere): A multicentre, open‐label, phase 2 randomised trial. Lancet Oncol 2016;17:791–800. - PubMed